A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...